O	0	4	Role
O	5	7	of
B-intervention	8	17	Mitomycin
I-intervention	18	19	C
O	20	22	in
O	23	33	Preventing
B-condition	34	42	Capsular
I-condition	43	54	Contracture
O	55	57	in
O	58	65	Implant
O	65	66	-
O	66	71	Based
O	72	86	Reconstructive
O	87	93	Breast
O	94	101	Surgery
O	101	102	:
O	103	104	A
O	105	115	Randomized
O	116	126	Controlled
O	127	132	Trial
O	132	133	.

O	134	142	Capsular
O	143	154	contracture
O	155	165	represents
O	166	169	the
O	170	174	most
O	175	183	frequent
O	184	196	complication
O	197	202	after
O	203	210	implant
O	210	211	-
O	211	216	based
O	217	223	breast
O	224	238	reconstruction
O	238	239	.

O	240	242	An
O	243	255	experimental
O	256	261	study
O	262	264	on
O	265	269	mice
O	270	282	demonstrated
O	283	287	that
O	288	295	capsule
O	296	305	formation
O	306	312	around
O	313	319	breast
O	320	328	implants
O	329	331	is
O	332	344	considerably
O	345	355	diminished
O	356	361	after
O	362	369	topical
O	370	381	application
O	382	384	of
O	385	394	mitomycin
O	395	396	C
O	396	397	.

O	398	401	The
O	402	409	authors
O	410	419	conducted
O	420	421	a
O	422	432	randomized
O	433	443	controlled
O	444	452	clinical
O	453	458	trial
O	459	472	investigating
O	473	476	the
O	477	485	efficacy
O	486	488	of
O	489	498	mitomycin
O	499	500	C
O	501	503	in
O	504	512	reducing
O	513	521	capsular
O	522	533	contracture
O	534	539	rates
O	540	549	following
O	550	557	implant
O	557	558	-
O	558	563	based
O	564	570	breast
O	571	585	reconstruction
O	586	591	after
O	592	602	mastectomy
O	603	606	for
O	607	613	breast
O	614	620	cancer
O	620	621	.

O	622	625	The
O	626	633	authors
O	634	644	randomized
O	645	648	all
O	649	654	women
B-age	655	660	older
I-age	661	665	than
I-age	666	668	18
I-age	669	674	years
B-eligibility	675	684	scheduled
I-eligibility	685	688	for
I-eligibility	689	692	the
I-eligibility	693	699	second
I-eligibility	700	705	stage
I-eligibility	706	708	of
I-eligibility	709	711	an
I-eligibility	712	719	implant
I-eligibility	719	720	-
I-eligibility	720	725	based
I-eligibility	726	732	breast
I-eligibility	733	747	reconstruction
I-eligibility	748	753	after
I-eligibility	754	764	mastectomy
I-eligibility	765	768	for
I-eligibility	769	775	breast
I-eligibility	776	782	cancer
O	783	785	at
O	786	789	the
O	790	798	National
O	799	805	Cancer
O	806	815	Institute
O	816	818	in
B-location	819	824	Milan
O	825	829	from
O	830	837	October
O	838	840	of
O	841	845	2005
O	846	848	to
O	849	857	February
O	858	860	of
O	861	865	2010
O	866	868	to
O	869	876	receive
O	877	879	or
O	880	883	not
O	884	891	receive
O	892	895	the
O	896	903	topical
O	904	915	application
O	916	918	of
O	919	928	mitomycin
O	929	930	C
O	931	937	during
O	938	945	surgery
O	945	946	.

O	947	950	The
O	951	958	authors
O	959	967	assessed
O	968	976	capsular
O	977	988	contracture
O	988	989	,
O	990	995	major
O	996	1009	postoperative
O	1010	1023	complications
O	1023	1024	,
O	1025	1028	and
O	1029	1038	aesthetic
O	1039	1046	outcome
O	1046	1047	.

O	1048	1051	The
O	1052	1059	authors
O	1060	1070	randomized
B-total-participants	1071	1074	322
O	1075	1083	patients
O	1084	1086	to
O	1087	1094	receive
O	1095	1104	mitomycin
O	1105	1106	C
O	1107	1109	or
O	1110	1113	not
O	1114	1116	at
O	1117	1120	the
O	1121	1127	second
O	1128	1133	stage
O	1134	1136	of
O	1137	1144	implant
O	1144	1145	-
O	1145	1150	based
O	1151	1157	breast
O	1158	1172	reconstruction
O	1172	1173	.

B-intervention-participants	1174	1177	One
I-intervention-participants	1178	1185	hundred
I-intervention-participants	1186	1191	sixty
I-intervention-participants	1191	1192	-
I-intervention-participants	1192	1195	two
O	1196	1204	patients
O	1205	1209	were
O	1210	1219	allocated
O	1220	1222	to
O	1223	1226	the
O	1227	1236	mitomycin
O	1237	1238	C
O	1239	1244	group
O	1245	1248	and
B-control-participants	1249	1252	160
O	1253	1261	patients
O	1262	1266	were
O	1267	1276	allocated
O	1277	1279	to
O	1280	1283	the
B-control	1284	1291	control
I-control	1292	1297	group
O	1297	1298	.

O	1299	1302	The
B-outcome	1303	1311	relative
I-outcome	1312	1316	risk
I-outcome	1317	1319	of
I-outcome	1320	1328	capsular
I-outcome	1329	1340	contracture
O	1341	1343	in
O	1344	1347	the
O	1348	1357	mitomycin
O	1358	1359	C
O	1360	1365	group
O	1366	1369	was
O	1370	1371	0
O	1371	1372	.
O	1372	1374	92
O	1375	1376	(
O	1376	1378	95
O	1379	1386	percent
O	1387	1389	CI
O	1389	1390	,
O	1391	1392	0
O	1392	1393	.
O	1393	1395	60
O	1396	1398	to
O	1399	1400	1
O	1400	1401	.
O	1401	1403	41
O	1403	1404	)
O	1404	1405	.

B-outcome	1406	1411	Major
I-outcome	1412	1425	complications
O	1426	1433	leading
O	1434	1436	to
B-outcome	1437	1451	reintervention
O	1451	1452	,
B-outcome	1453	1462	oncologic
I-outcome	1463	1471	outcomes
O	1471	1472	,
O	1473	1476	and
B-outcome	1477	1486	aesthetic
I-outcome	1487	1495	outcomes
O	1496	1500	were
O	1501	1511	comparable
O	1512	1519	between
O	1520	1523	the
O	1524	1527	two
O	1528	1534	groups
O	1534	1535	.

O	1536	1540	This
O	1541	1543	is
O	1544	1547	the
O	1548	1553	first
O	1554	1559	trial
O	1560	1569	reporting
O	1570	1574	data
O	1575	1580	about
O	1581	1584	the
O	1585	1588	use
O	1589	1591	of
O	1592	1601	mitomycin
O	1602	1603	C
O	1604	1606	in
O	1607	1613	breast
O	1614	1628	reconstructive
O	1629	1636	surgery
O	1637	1639	in
O	1640	1641	a
O	1642	1650	clinical
O	1651	1658	setting
O	1658	1659	.

O	1660	1669	Mitomycin
O	1670	1671	C
O	1672	1677	seems
O	1678	1681	not
O	1682	1684	to
O	1685	1698	significantly
O	1699	1705	affect
O	1706	1714	capsular
O	1715	1726	contracture
O	1727	1731	rate
O	1732	1735	and
O	1736	1744	severity
O	1745	1754	following
O	1755	1762	implant
O	1762	1763	-
O	1763	1768	based
O	1769	1783	reconstructive
O	1784	1790	breast
O	1791	1798	surgery
O	1799	1801	at
O	1802	1805	the
O	1806	1812	tested
O	1813	1818	doses
O	1818	1819	.

O	1820	1831	Therapeutic
O	1831	1832	,
O	1833	1834	I
O	1834	1835	.
